Selective Pyrazine Ligands for α4β2 NNR Subtype Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds that interact with nicotinic acetylcholine receptors (NNRs) lack subtype selectivity, leading to adverse effects such as cardiovascular and gastrointestinal problems, addiction, and toxicity, while non-selective compounds fail to target α4β2 NNRs effectively for therapeutic benefits like enhanced cognitive function and pain control.
Innovation Solution
Development of specific compounds of formula (I) that selectively interact with α4β2 NNRs, comprising various substituents and linkages, which can be administered alone or with carriers to treat cognitive disorders and pain, offering agonist, antagonist, or partial agonist properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective NNR ligands are used, then broad receptor interaction is achieved, but adverse effects such as cardiovascular problems, gastrointestinal issues, addiction, and toxicity occur
Solution Approach 1:
The patent applies local quality by designing ligands with specific substituent patterns at defined positions on the pyrazine core structure. Different substituents (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12) are strategically placed to create localized interactions with specific residues in the α4β2 NNR binding site, enabling selective engagement with this particular receptor subtype while avoiding non-specific binding to other nAChR subtypes that mediate adverse effects
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters including substituent types, linker lengths, and spatial arrangements in the general formula (I) structure. These parameter modifications allow fine-tuning of the ligand's pharmacological profile to achieve optimal selectivity for α4β2 NNRs, transforming the broad-spectrum activity of non-selective ligands into targeted therapy with reduced side effects
2Reliability
If subtype-selective ligands are developed, then therapeutic benefits for cognitive function and pain control are achieved, but compound complexity increases
Solution Approach 1:
The patent applies universality by creating a general formula (I) framework that can accommodate multiple substituent variations while maintaining the core pyrazine-based pharmacophore. This universal scaffold enables a single molecular architecture to achieve multiple therapeutic functions including cognitive enhancement, pain control, and烟瘾 cessation by selectively targeting α4β2 NNRs, reducing the need for entirely separate drug designs for different indications
Solution Approach 2:
The patent employs segmentation by dividing the ligand structure into distinct functional modules: a core pyrazine ring system, variable substituent groups at specific positions, and linker regions. This modular segmentation allows independent optimization of each component for selectivity and activity, simplifying the drug design process despite the overall molecular complexity required for α4β2 NNR targeting
Data Source
AI summary
The present application describes selective ligands of formula (I)for neuronal nicotinic receptors (NNRs), more specifically for the α4β2 NNR subtype, compositions thereof, and methods of using the same, wherein X, R1, X, R2, R3, L1, m, n, p, and q are defined in the specification.